Subgroup analysis of large trials can guide further research: a case study of vitamin E and pneumonia by Hemilä, Harri & Kaprio, Jaakko
© 2011 Hemilä and Kaprio, publisher and licensee Dove Medical Press Ltd. This is an Open Access 
article which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Epidemiology 2011:3 51–59
Clinical Epidemiology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
51
OriginAL rEsEArCH
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/CLEP.S16114
subgroup analysis of large trials can guide further 
research: a case study of vitamin E and pneumonia
Harri Hemilä 
Jaakko Kaprio
Department of Public Health, 
University of Helsinki, Helsinki, 
Finland
Correspondence: Harri Hemilä 
Department of Public Health,  
University of Helsinki, POB 41,  
Helsinki, Fin-00014, Finland 
Tel +358 9 191 27573 
Fax +358 9 191 27570 
Email harri.hemila@helsinki.fi
Background: Biology is complex and the effects of many interventions may vary between 
population groups. Subgroup analysis can give estimates for specific populations, but trials are 
usually too small for such analyses.
Purpose: To test whether the effect of vitamin E on pneumonia risk is uniform over subgroups 
defined by smoking and exercise.
Methods: The Alpha-Tocopherol Beta-Carotene Cancer Prevention Study examined the effects 
of vitamin E (50 mg per day) and β-carotene (20 mg per day) on lung cancer in 29,133 male 
smokers aged 50–69 years using a 2 × 2 factorial design. The trial was conducted among the 
general community in Finland during 1985–1993; the intervention lasted for 6.0 years (median). 
In the present study, we tested the uniformity of vitamin E effect on the risk of hospital-treated 
pneumonia (898 cases) by adding a dummy variable to allow each subgroup its own vitamin E 
effect in a Cox model covering all participants.
Results: Vitamin E effect was not uniform over eight subgroups defined by baseline smoking 
(5–19 vs $20 cigarettes per day), age of smoking initiation (#20 vs $21 years), and exercise 
during leisure time (yes vs no). Vitamin E decreased pneumonia risk by 69% (95% CI: 43% to 
83%) among participants who had the least exposure to smoking and exercised during leisure 
time. Vitamin E increased pneumonia risk by 79% (95% CI: 27% to 150%) among those who 
had the highest exposure to smoking and did not exercise.
Limitations: Although the evidence of heterogeneity is strong, it is not evident to what 
extent the estimates of effect or the limits between the subgroups can be extrapolated to other 
populations.
Conclusion: Subgroup analysis of large trials should be encouraged, though caution is needed in 
the interpretation of findings. The role of vitamin E in susceptibility to pneumonia in   physically 
active nonsmokers warrants further study.
Trial registration: ClinicalTrials.gov NCT00342992.
Keywords: vitamin E, pneumonia, smoking, leisure time exercise, α-tocopherol, β-carotene, 
subgroup analysis
Introduction
The size of a controlled trial is usually based on a power calculation, the goal of 
which is to determine the minimal number of participants needed to test whether an 
overall difference exists between the intervention and control groups. Such trials are 
too small to test subgroup differences. Furthermore, carrying out numerous subgroup 
comparisons leads to the multiple testing problem. Such reasoning is the major cause 
for discouraging subgroup analyses.1–5Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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The above argument has limitations, however. For e  xample, 
if a trial collects data on a secondary outcome which are much 
more numerous than the primary outcome, say lung cancer, 
subgroup analysis on the secondary o  utcome, such as the 
common cold,6 does not suffer from low statistical power. 
Furthermore, most controlled trials study the effect of drugs 
having a specific biochemical target within patients who are 
narrowly selected, and a large within-trial v  ariation in the 
effect may be unlikely in such cases. However, it is possible 
that the within-trial variation in the effect is   substantially 
greater for interventions that have complex and broad effects 
on the human system, in particular when the effects are stud-
ied in heterogeneous populations. Thus, while reasons exist 
for being cautious about subgroup analysis in general, there 
are conditions when subgroup analyses may be justified.
Previously, we explored the effect of vitamin E on p  neumonia 
risk among the 29,133 male smokers of the Alpha-Tocopherol 
Beta-Carotene [ATBC] Study.7,8 We found significant modifi-
cation of vitamin E effect by age of smoking initiation, in that 
the vitamin reduced the risk in those who started smoking at 
a late age and, within this subgroup, baseline smoking further 
modified the effect so that the   benefit was greatest among those 
who smoked the least.9 Since physical activity leads to oxidative 
stress,10 we separately hypothesized that vitamin E might reduce 
pneumonia risk among physically active ATBC Study partici-
pants, and found that the vitamin halved the risk in those who 
exercised during leisure time.11 These findings indicate that ciga-
rette smoking and exercise might modify the effect of vitamin 
E on pneumonia risk. However, since several comparisons were 
made, the multiple testing problem cannot be entirely dismissed. 
Therefore, in this paper we analyze the subgroup differences in 
all ATBC Study participants simultaneously.
If there is firm evidence that the effect of vitamin E 
s  upplementation on health outcomes of the ATBC par-
ticipants is heterogeneous, this would imply that subgroup 
analyses in other large-scale trials on vitamin E, and possibly 
in large-scale trials on other subjects, should be encouraged 
rather than discouraged.
Material and methods
Participants
The rationale, design, and methods of the ATBC Study 
e  xamining the effects of vitamin E (dl-α-tocopheryl 
a  cetate, AT, 50 mg/day) and β-carotene (BC, 20 mg/day) 
on the i  ncidence of lung cancer and other cancers have 
been described in detail.7–9 The ATBC Study is registered at 
C  linicalTrials.gov under the identifier NCT00342992.
In brief, to be eligible, male participants aged 50–69 years 
had to smoke $5 cigarettes per day at entry, and those 
enrolled in the trial (N = 29,133) were randomized to one 
of four intervention arms and administered placebo, AT, 
BC, or AT + BC, using a 2 × 2 factorial design. Compared 
with baseline levels, supplementation increased the serum 
level of α-tocopherol by 50%.7,8 The intervention continued 
for 5 to 8 years until April 1993. The trial was approved by 
the review boards of the participating institutions and all 
participants gave written informed consent. Compliance 
with supplementation was high: some 90% of the subjects 
took more than 90% of their prescribed capsules during their 
active participation in the trial.7,8
Baseline characteristics
Before randomization at baseline, the participants c  ompleted 
questionnaires on medical and smoking histories and g  eneral 
background characteristics. A detailed dietary history 
questionnaire was completed that provided data regarding 
vitamins C and E, and coffee consumption.12 Age of smoking 
initiation was not available for seven participants and dietary 
data for 2,022 participants.
Previously, we found that dichotomization of the age of 
smoking initiation with the cutoff point at 21 years appropri-
ately captured the variation of the vitamin E effect,9 and the 
same cutoff was used in this study. Although smoking is a con-
tinuous variable, it is heavily clustered to multiples of 20 (and 
10) cigarettes per day. In this study, we dichotomized cigarette 
smoking to 5–19 cigarettes per day and to $20 per day. As we 
recognized that in both cases dichotomization leads to a loss 
of information of the continuous variables, we examined the 
effect of vitamin E in smaller ranges in Tables 2 and 3.
The baseline questionnaire on physical activity during 
leisure time was a modification of that used originally 
in the Gothenburg study focusing on cardiovascular 
  diseases.13 The intensity of average physical activity d  uring 
leisure time over the previous 12 months was enquired 
about using the following alternatives: 1) light: reading, 
  watching TV, listening to the radio, or going to movies, ie, 
activities that are not p  hysically demanding; 2) moderate: 
w  alking, fi  shing, hunting, or gardening quite regularly; and 
3) heavy: actual physical exercise, such as jogging, skiing, 
swimming, gymnastics, and court and field sports quite 
regularly. In the current analyses we combined answers 
2) [n = 15,191] and 3) [n = 1,744] to the category “exercise 
during leisure time”. Data on exercise were not available 
for 14 participants.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Outcome and follow-up time
The events for this study, the first hospital-treated cases of 
pneumonia after randomization, were ascertained from the 
national Hospital Discharge Register using the unique personal 
identification numbers for linkage (see details in Hemilä et al)9. 
Pneumonia cases recorded in the Hospital Discharge Register 
reflect clinically more severe cases of greater health and eco-
nomic significance, whereas less severe cases of pneumonia 
treated as outpatients are not recorded in the Register. Use of 
the Hospital Discharge Register allowed for the obtaining of 
information on pneumonia in all study participants irrespective 
of whether they continued in or had dropped out of the trial.
Follow-up time for each participant began from the day of 
randomization, and continued until the date of first hospital 
discharge for pneumonia, death, or the end of the trial, April 
30, 1993, whichever came first. The median follow-up time 
of the participants was 6.0 years, and there was a total of 
167,968 person-years of observation.
statistical methods
We estimated the effect of vitamin E supplementation on 
pneumonia incidence through Cox models. We calculated 
the risk ratio (RR) and the 95% confidence interval (CI) 
of the RR using the PROC PHREG program of the SAS 
  package of programs (release 8.2, SAS Institute, Inc., Cary, 
NC). No covariates were included in the models analyzing 
the treatment effects. As to supplementation, we carried 
out the analyses following the intention-to-treat (ITT) 
principle.
In Table 1, we compared the trial participants administered 
vitamin E (AT and AT + BC) with those not r  eceiving vitamin 
E (the no-vitamin E participants; placebo and BC). Since, 
in Table 3, we observed that AT and BC supplementations 
interacted, we restricted further subgroup analyses of Table 3 
to the no-BC participants (AT and placebo arms). Because of 
this interaction, we also re-tested the heterogeneity of Table 1 
by restricting to the no-BC participants.
Table 1 The effect of vitamin E on pneumonia incidence by level of cigarette smoke exposure and exercise during leisure time: ATBC 
study 1985–1993
Age of smoking  
initiation (years)
Cigarettes per  
day at baseline
Effect of vitamin E
Exercise during leisure time
Yes No
$21 5–19 rra 0.31 0.85
(95% Ci)a (0.17, 0.57) (0.44, 1.64)
Cases of pneumoniab 14/43 17/19
no. of menc 2,216 1,043
$21 $20 rra 0.84 0.86
(95% Ci)a (0.48, 1.46) (0.50, 1.49)
Cases of pneumoniab 24/27 24/28
no. of menc 2,445 1,763
#20 5–19 rra 1.24 1.05
(95% Ci)a (0.87, 1.78) (0.71, 1.56)
Cases of pneumoniab 68/56 51/50
no. of menc 4,602 2,688
#20 $20 rra 0.88 1.35
(95% Ci)a (0.67, 1.15) (1.06, 1.73)
Cases of pneumoniab 97/110 152/115
no. of menc 7,669 6,686
Notes: aThe Cox model comparing participants who received vitamin E with those who did not; bA/B refers to A cases of pneumonia among the vitamin E participants 
and B cases of pneumonia among the no-vitamin E participants. Data on age of smoking initiation or exercise were missing from two pneumonia cases among the vitamin E 
participants and from one case among the no-vitamin E participants; these cases are not included in this table; cThe number of participants in the vitamin E and no-vitamin E 
groups was the same within 5% accuracy in each of the eight groups. The uniformity of the vitamin E effect was tested by adding a dummy variable for vitamin E effect in 
seven groups of the table, allowing each of the eight groups their own vitamin E effect. The regression model was improved by χ2(7 df) = 26.6, P = 0.0004, compared to the 
model with a uniform vitamin E effect. Heterogeneity is mainly caused by the upper-left and lower-right cells: the addition of only these two cells improved the model by 
χ2(2 df) = 23.4. The difference between the above two models is fully explained by chance: χ2(5 df) = 3.2. The addition of the third-order interaction term, between vitamin E 
supplementation, age of smoking initiation, cigarettes per day, and leisure time exercise, to the model containing all lower level interaction terms, improved the regression 
model by χ2(1 df) = 5.4, P = 0.02. since vitamin E and β-carotene supplementations interact in the lower-right cell (see Table 3), we also tested the uniformity of vitamin E 
effect among the no-β-carotene participants (n = 14,564). Adding a dummy variable for vitamin E effect in seven groups of the table improved the model by χ2(7 df) = 22.8,   
P = 0.002. Adding only the upper-left and lower-right cells improved the model by χ2(2 df) = 17.8, indicating that the effect of vitamin E is restricted to the upper-left and 
lower-right cells. The difference between the two models is fully explained by chance: χ2(5 df) = 5.0. nevertheless, adding the third-order interaction term to a model 
containing all lower level interactions did not significantly improve the model: χ2(1 df) = 2.0, P = 0.16. Vitamin E and β-carotene supplementations did not interact in cells of 
this table other than the lower-right cell.
Abbreviations: RR, risk ratio; CI, confidence interval.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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To test the statistical significance of interaction between 
vitamin E supplementation and potential modifying factors, 
we first added vitamin E and the modifying factor to the 
regression model. The statistical significance of the interac-
tion was thereafter calculated from the change in -2 × log 
(likelihood) when the interaction term for vitamin E supple-
mentation and the modifying factor were added to the model. 
In our subgroup analyses in Tables 2 and 3, we split the 
subgroup variables at levels leading to a reasonably similar 
number of cases in the control groups.
Nelson-Aalen cumulative hazard functions were con-
structed using the STATA sts program (Release 9, Stata 
Corp, College Station, TX). Two-tailed P-values are 
presented.
Results
Among all ATBC participants, the cases of pneumonia were 
identically divided between the vitamin E and no-vitamin E 
groups: 449 vs 449, corresponding to RR = 1.00 (95% CI: 
0.88, 1.14).
We divided the participants into eight subgroups on 
the basis of age of smoking initiation, level of smoking at 
the baseline of the trial, and exercise during leisure time 
(Table 1). We tested the uniformity of the vitamin E effect 
by adding a dummy variable for vitamin E effect in seven 
groups of the table, and this significantly improved the Cox 
model (P = 0.0004). The heterogeneity in Table 1 is fully 
explained by the upper-left and lower-right corners, ie, by 
the opposite corners of the table. Furthermore, the third-level 
interaction term between vitamin E supplementation, age 
of smoking initiation, level of smoking, and exercise was 
significant when comparing the vitamin E and no-vitamin E 
participants. Since the effect of vitamin E was restricted to 
the upper-right and lower-left corners, we analyzed these 
two groups further.
Among the 2,216 participants who initiated smoking at a 
late age, smoked less than a pack of cigarettes per day, and 
exercised during leisure time, vitamin E supplementation 
reduced pneumonia risk by 69% (upper-left cell in Table 1; 
Figure 1). The estimated effect of vitamin E in this subgroup 
Table 2 The effect of vitamin E on pneumonia incidence in ATBC participants who initiated smoking at $21 years, smoked 5–19 
cigarettes per day, and exercised during leisure time
Subgroup No. of mena Cases of pneumoniab Effect of vitamin E
RR (95% CI)c Test for  
interaction (P)
All 2,216 14/43 0.31 (0.17, 0.57)
β-Carotene supplementation
no 1,093 6/19 0.32 (0.13, 0.80) 0.9
Yes 1,123 8/24 0.30 (0.13, 0.66)
Cigarettes (1/day)
5–11 1,110 6/18 0.31 (0.12, 0.78) 1.0
12–19 1,106 8/25 0.31 (0.14, 0.69)
Age of smoking initiation (years)
21–25 1,563 9/28 0.30 (0.14, 0.63) 0.9
26–60 653 5/15 0.34 (0.12, 0.92)
Age at baseline (years)
50–64 1,810 8/23 0.33 (0.14, 0.73) 0.9
65–69 406 6/20 0.30 (0.12, 0.75)
Dietary vitamin E (mg/day)d
,9 570 5/20 0.26 (0.10, 0.69) 0.6
$9 1,486 8/20 0.36 (0.16, 0.81)
Dietary vitamin C (mg/day)d
,100 1,030 8/20 0.37 (0.16, 0.85) 0.5
$100 1,026 5/20 0.23 (0.09, 0.62)
Coffee (mL/day)d
,500 999 9/18 0.47 (0.21, 1.05) 0.12
$500 1,057 4/22 0.17 (0.06, 0.48)
Notes: aThe number of participants in the vitamin E and no-vitamin E groups was the same within 8% accuracy in all subgroups shown; bA/B refers to A cases of pneumonia 
among the vitamin E participants and B cases of pneumonia among the no-vitamin E participants; cThe Cox model comparing participants who received vitamin E with those 
who did not; dData on diet were missing for 160 participants, which included one case of pneumonia in the vitamin E group and three cases in the no-vitamin E group.
Abbreviations: RR, risk ratio; CI, confidence interval.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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was robust in several further subgroup analyses. The effect 
was not modified by BC supplementation, age, or dietary 
vitamins C and E (Table 2). Dividing the participants by the 
age of smoking initiation and baseline smoking also led to 
compatible effects within the smaller subgroups. Previously, 
we found that coffee consumption significantly modified the 
benefit of vitamin E in those who started smoking at a late 
age.9 The subgroup differences in Table 2 are in line with 
the earlier findings, but not significantly.
Among the 6,686 participants who initiated smoking at 
an early age, smoked a pack of cigarettes daily or more, and 
did not exercise, vitamin E increased pneumonia risk by 35% 
when compared with the no-vitamin E group (lower-right cell 
in Table 1). However, in this subgroup the vitamin E effect 
was modified by BC supplementation so that the harm of 
vitamin E was restricted to those who were not administered 
BC (Table 3). Therefore, we restricted the further subgroup 
analyses of Table 3 to the no-BC participants. Among the 
no-BC participants, vitamin E increased pneumonia risk by 
79%, and this effect was robust in further subgroup analyses 
(Table 3).
Previously, we hypothesized that the marginally signifi-
cant 14% increase in pneumonia risk among those ATBC 
participants who started smoking at an early age (n = 21,657; 
the four lowest cells in Table 1) might correspond to a more 
unambiguous harmful effect among low-weight participants, 
based on an assumption of dose-dependency.14 Then we 
found that vitamin E increased pneumonia risk in participants 
weighing less than 60 kg. Unexpectedly, vitamin E also 
increased pneumonia risk at the opposite end of the weight 
scale, among those weighing over 100 kg.14 Furthermore, 
in both groups, harm caused by vitamin E was restricted to 
those who had a dietary vitamin C intake above the median. 
Therefore, we examined whether weight and vitamin C intake 
might modify the effect of supplementation outside of the 
lower-right corner in Table 1.
Table 3 The effect of vitamin E on pneumonia incidence in ATBC participants who initiated smoking at #20 years, smoked $20 
cigarettes per day, and did not exercise during leisure time
Subgroup No. of mena Cases of pneumoniab Effect of vitamin E
RR (95% CI)c Test for  
interaction (P)
All 6,686 152/115 1.35 (1.06, 1.7)
β-Carotene supplementation 
no 3,371 89/51 1.79 (1.27, 2.5) 0.02
Yes 3,315 63/64 1.01 (0.71, 1.4)
restriction to the no-β-carotene participants:
no β-carotene 3,371 89/51 1.79 (1.27, 2.5)
Cigarettes (1/day)
20–25 2,269 62/36 1.78 (1.18, 2.7) 1.0
26–80 1,102 27/15 1.83 (0.97, 3.5)
Age of smoking initiation (years)
6–17 1,616 48/26 1.94 (1.20, 3.1) 0.6
18–20 1,755 41/25 1.64 (1.00, 2.7)
Age at baseline (years)
50–59 2,466 55/31 1.84 (1.19, 2.9) 0.8
60–69 905 34/20 1.70 (0.98, 3.0)
Dietary vitamin E (mg/day)d
,9 1,231 31/22 1.52 (0.88, 2.6) 0.5
$9 1,909 49/26 1.90 (1.18, 3.1)
Dietary vitamin C (mg/day)d
,70 1,229 38/22 1.76 (1.04, 3.0) 0.9
$70 1,911 42/26 1.69 (1.03, 2.8)
Coffee (mL/day)d
,500 1,188 38/20 1.95 (1.13, 3.4) 0.5
$500 1,952 42/28 1.56 (0.96, 2.5)
Notes: aThe number of participants in the vitamin E and no-vitamin E groups was the same within 5% accuracy in all subgroups shown; bA/B refers to A cases of pneumonia 
among the vitamin E participants and B cases of pneumonia among the no-vitamin E participants; cThe Cox model comparing participants who received vitamin E with those 
who did not; dData on diet were missing for 231 participants, which included nine cases of pneumonia in the vitamin E group and three cases in the no-vitamin E group.
Abbreviations: RR, risk ratio; CI, confidence interval.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Of the low-weight high vitamin C participants, 72% 
(337 of 468) were outside the lower-right corner of Table 1; 
in these 337 participants there were 19 pneumonia cases 
among the vitamin E and eight cases among the no-vitamin E 
participants (RR = 2.7, 95% CI: 1.18–6.2). Of the overweight 
high vitamin C participants, 65% (397 of 613) were outside 
the lower-right corner of Table 1; in these 397 participants 
there were 10 pneumonia cases among the vitamin E and 
one case among the no-vitamin E participants (P = 0.01, 
Fisher’s test). Consequently, weight and dietary vitamin 
C appear to modify the effect of vitamin E independent of 
smoking and exercise.
Discussion
The numbers of pneumonia cases in the ATBC Study were 
equally distributed between the vitamin E and no-vitamin E 
participants, indicating a lack of overall effect with great 
accuracy. However, in this study we have shown that the effect 
of vitamin E is not uniformly nil over all the ATBC Study 
population. Depending simultaneously on the two different 
measures of cigarette smoking and on the level of exercise, 
vitamin E supplementation decreased, increased or had no 
effect on the incidence of pneumonia (Table 1).
Among those who had the least exposure to smoking and 
exercised during leisure time, vitamin E decreased the risk 
of pneumonia by 69%. This group covers 8% of the ATBC 
Study participants. The effect estimate was robust in further 
subgroup analyses (Table 2).
The group that had the highest exposure to smoking and 
did not exercise covered 23% of the ATBC participants. In 
this group, vitamin E increased pneumonia risk by 79% in 
the no-BC participants (Table 3). This effect estimate was 
also robust in further subgroup analyses, however simulta-
neous BC supplementation nullified the harmful effects of 
vitamin E.
In our subgroup analysis focusing on smoking and exer-
cise, 69% of the ATBC participants fell into the six middle 
groups that were consistent with vitamin E having no effect 
(Table 1). Nevertheless, it is possible that there are further 
modifying factors in addition to smoking and physical activ-
ity. Previously, we found that coffee drinking modified the 
effect of vitamin E among those who started smoking at a 
late age.9 Among those who started smoking at an early age, 
weight and dietary vitamin C intake modified the vitamin E 
supplementation effect.14 The current analyses are not incon-
sistent with these earlier subgroup findings. Thus, it seems 
possible that vitamin E can affect pneumonia risk in some 
groups of people depending on six or more modifying fac-
tors meaning that the modification is complex and does not 
follow a simple multiplicative model.
It is often suggested that subgroup findings should be 
trusted only when they are replicated in other trials. Although 
such a suggestion seems sound, the heterogeneity we found 
in the effect of vitamin E on pneumonia suggests that t  esting 
a subgroup difference in another sample of people can be 
all but simple. When the effect of vitamin E may depend 
simultaneously on six or more modifying factors, the find-
ings for the first-level interactions depend on the selection 
of participants.
For example, in the whole ATBC Study, baseline smok-
ing did not modify the effect of vitamin E (P = 0.2).9 How-
ever, Table 1 indicates that baseline smoking modifies the 
vitamin E effect conditionally on the age of smoking initiation 
and the level of exercise. This means that depending on the 
composition of the population, baseline smoking may or may 
not modify the effect of vitamin E. Similarly, we previously 
found that vitamin E halved the risk of pneumonia in ATBC 
participants who exercised during leisure time;11 however, 
Table 1 indicates that this effect is conditional on low level of 
exposure to smoking. On the basis of these examples, replica-
tion is not a universally valid method for deciding whether the 
subgroup differences observed in one trial are real or not.
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Figure 1 Vitamin E and pneumonia risk in ATBC study participants who started 
smoking at $21 years, smoked 5–19 cigarettes per day, and exercised (n = 2,216). 
nelson-Aalen cumulative hazard functions for vitamin E and no-vitamin E groups are 
shown. Each step indicates one case of pneumonia. For the difference between the 
two survival curves, the logrank test gives P = 0.00005. The survival curves are cut at 
7.2 years because the number of participants declines abruptly thereafter (no cases 
after 6.8 years). At six-year follow-up 576 and 535 participants remained in the 
vitamin E and the no-vitamin E groups, respectively.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Peto et al argued that “believing that a treatment effect 
exists in one stratum of patients, even though no overall 
significant treatment effect exists, is a common error”.4 This 
comment may be sound with respect to rather small therapeu-
tic trials. However, Table 1 and our previous ATBC Study 
subgroup analyses6,9,11,14–17 show that there can be strong 
evidence of vitamin E effect in specific groups of people, 
even though no overall effect exists. Accordingly, Peto et al’s 
argument should not be taken as a universal objection to 
analyzing subgroups in the absence of overall effect.
Several investigators have strongly discouraged subgroup 
analysis.1–5 However, other authors have considered that 
a universal denial of subgroup analysis is an exaggerated 
r  eaction. Feinstein wanted to “rescue the scientific impor-
tance of valid pathophysiologic subgroups from being for-
gotten or destroyed by excessive vehemence in suggestions 
that all subgroups are evil”.18 Lagakos noted that “avoiding 
any presentation of subgroup analysis because of their his-
tory of being overinterpreted is a steep price to pay for a 
problem that can be remedied by more responsible analysis 
and reporting”.19 Rothwell responded to popular arguments 
against subgroup analysis and described situations where 
subgroup analysis seems to be justified.20
Altman considered that biological plausibility is a weak 
criterion when deciding whether a subgroup finding is likely 
to be real, since, according to him, physicians seem able to 
find a biologically plausible explanation for any finding.2 
There is much room for speculation at the biochemical 
level, because the number of genes and their effects is huge, 
and Altman’s argument can have validity in such a context. 
However, the number of variables relevant at the population 
level of biology is much more limited. For example, few 
factors compare with the importance of smoking as a factor 
influencing the health of the lungs. Physical activity is also a 
fundamentally important factor determining health. Smoking 
affects the metabolism of vitamin E21 and sporadic physical 
stress causes oxidative stress which is not compensated by 
an increase in antioxidative enzyme levels, unlike regular 
physical activity.10 Therefore, both smoking and exercise 
are plausible modifying factors for the effects of vitamin E 
supplementation, which increases the credibility of the het-
erogeneity seen in Table 1.
Previously, two small trials examined the effect of 
v  itamin E on respiratory infections in elderly people, both 
with less than 700 participants and lasting for about one year. 
In the first, Meydani et al calculated 13 P-values for ITT 
c  omparisons between 200 mg/day vitamin E and p  lacebo 
groups, and only one of them suggested that vitamin E 
might reduce the incidence of respiratory infections, yet very 
  marginally so (P = 0.048).22 In the second, Graat et al found 
that 200 mg/day of vitamin E did not influence the incidence 
of respiratory infections, yet made the symptoms more 
severe (P = 0.02).23 Because both of these trials are small 
and there are differences in outcome definitions etc, it is not 
possible to decide whether their findings are inconsistent 
or not. Graat et al’s findings indicating harmful effects of 
  vitamin E conflict with the wide spread belief that the vitamin 
is beneficial, or at least not harmful.24 Therefore, it is not 
obvious whether Graat et al’s findings should be interpreted 
as a reflection of real harm or as a result of chance. Given the 
strong evidence of heterogeneity we observed in the effect of 
vitamin E on pneumonia (Table 1) and on the common cold,6 
it seems plausible that the harmful effects observed by 
Graat et al are real and are explained by the selection of 
participants, but do not reflect a universal harmful effect of 
vitamin E. In this respect, the observed heterogeneity in the 
ATBC Study can influence the interpretation of smaller trials. 
Nevertheless, we are skeptical as regards the possibility of 
extrapolating the effect estimates and the exact limits of the 
subgroups of Table 1 to other contexts.
Although the division of participants on the basis of 
baseline physical activity and smoking is sound, both of these 
factors can change with time. Some participants stopped 
exercising or smoking over the several-years-long follow-up, 
yet they remained classified in the same subgroups. This phe-
nomenon can dilute the differences between the subgroups 
and shift the estimates of effect closer to unity; however, it 
cannot explain the significant heterogeneity observed when 
the participants are divided by the baseline measurements. 
Furthermore, exercise and smoking are correlated with 
numerous other life style variables and we cannot dismiss 
the possibility that other life style factors might be behind the 
heterogeneity observed in Table 1. Nevertheless, this concern 
does not challenge the evidence indicating that substantial 
heterogeneity exists across various population groups in 
the effect of vitamin E on pneumonia risk, even if the real 
modifying variables might be different from those used for 
defining the subgroups of Table 1.
The ATBC Study included 29,133 participants which 
is over 40 times more than the number of participants in 
the Meydani et al22 and Graat et al23 trials. In this respect, a 
large trial can be considered as a series of smaller trials when 
there is sound justification for setting the borders between the 
subgroups. A particular strength of a subgroup analysis of Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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a large trial is that the intervention and outcome definitions 
are identical over the trial. Therefore, subgroup analysis of 
a large trial can yield much more valid explanations for the 
heterogeneity of effect compared with the analysis of the 
heterogeneity of small trials that have numerous concurrent 
differences.
For many diseases, recognized risk factors account for at 
best only a modest fraction of variation in disease risk. Much 
effort is put into identifying new factors, either environmental 
or genetic. Our analyses indicate that complex patterns of 
interaction, perhaps in a context-specific manner, may also 
contribute to disease risk. Such effects may thus account for 
some of the unexplained variability of disease risk.
Our subgroup analyses of the respiratory infections of 
ATBC participants6,9,14,15 made it also possible to hypothesize 
that the identified modifying factors might modify the effect 
of vitamin E on the mortality of these participants. We found 
that, conditional on a high level of dietary vitamin C intake, 
age modified the effect of vitamin E on mortality.16,17 Thus, 
we could partially extrapolate the modifying factors identi-
fied in the subgroup analyses on respiratory infections to an 
outcome that has a very weak relation to such infections.
Vandenbroucke pointed out that medical science has 
two divergent goals.25 First, controlled trials test whether 
an intervention works or not. Second, most basic medical 
science emphasizes discovery – searching for the biological 
mechanisms and causes of diseases, and for explanations in 
general. This divergence in views is relevant when consider-
ing a proper attitude to subgroup analysis. Evidently, great 
caution must be exercised when proposing a treatment on 
the basis of unanticipated subgroup findings. On the other 
hand, subgroup analysis can generate new hypotheses and 
direct research to new paths, which is the second goal of 
medical science. Refusing to conduct the subgroup analysis 
of large trials would lead to an inefficient use of data, the 
collection of which has required a substantial amount of 
resources.
Conclusion
The overall effect of vitamin E on pneumonia risk in the 
ATBC Study implies that there would be no justification for 
investing further resources into studying the topic because 
the narrow confidence interval rejects any substantial overall 
benefits (RR from 0.88 to 1.14). In contrast, our subgroup 
analysis suggests a path that should be explored: does 
vitamin E affect the incidence of pneumonia in physically 
active males who are nonsmokers or who have had only little 
exposure to smoking?
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